ReviewAntibiotics (Basel, Switzerland)2025
FDA-Approved Antibacterials and Echinocandins.
Review in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Halictine-II as a Potential Broad-Spectrum Antifungal and Antibacterial Agent.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Effects of Cholesterol and Solution pH on Daptomycin-bilayer Interactions.The Journal of membrane biology · 2026Article
- Nature-inspired biomaterial innovations to counter medical device-associated infections.Biomaterials science · 2026Review
- Self-Assembly of Peptides and Biomolecular Systems Into Functional Nanomaterials.Journal of peptide science : an official publication of the European Peptide Society · 2026Review
- The KW18 peptide acts as a dual antimicrobial and immunomodulatory therapeutic candidate in the context of antimicrobial resistance.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Design, synthesis, molecular docking, and antimicrobial evaluation of hybrid peptides incorporating unnatural amino acids with enhanced hydrophobic sidechains.RSC advances · 2026Article
- Integrative computational-experimental discovery and translation of antifungal peptides for multidrug-resistant fungi.Frontiers in microbiology · 2026Review
- Nanosystems for delivery of indolicidin peptide.Frontiers in medical technology · 2026Review
- Ultrastructural and Immunohistochemical Study on the Nephrotoxicity Following Intravitreal Administration of the Antifungal Agents Voriconazole and Micafungin in New Zealand White Rabbits.International journal of molecular sciences · 2025Article
- Bio-inspired biomaterial coating for enzyme responsive release of antimicrobial peptides.Materials today. Bio · 2025Article
- Current Status of the Application of Antimicrobial Peptides and Their Conjugated Derivatives.Molecules (Basel, Switzerland) · 2025Review
- Antimicrobial Peptides: An Emerging Hope in the Era of New Infections and Resistance.Antibiotics (Basel, Switzerland) · 2025Article
- Antifungal Effects of the Phloroglucinol Derivative DPPG Against PathogenicAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since 1955, a total of 12 peptide-based drugs with antimicrobial or antifungal properties have received approval from the Food and Drug Administration (FDA). Peptides present a promising opportunity to address serious infections that may be challenging to manage through other means. Peptides exhibit the capability to leverage various mechanisms, and in some cases, multiple mechanisms are employed for this purpose. Despite the initial approval dating back to 1955, the FDA recently approved an echinocandin peptide just last year. The ongoing approvals underscore the significance of peptides in addressing ongoing medical challenges. Approximately 22 peptide therapeutics with an antibacterial and antifungal spectrum are currently undergoing various phases of clinical trials, showing promising results. In this review, antimicrobial and antifungal peptides are analyzed in terms of their chemical structure, indication, mode of action, and development journey, concluding with their arrival in the pharmaceutical market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.